Gossamer Bio, Inc. logo

Gossamer Bio, Inc. (GOSS) Q1 2026 Earnings

GOSS·Reported May 18, 2026·Before market open

Gossamer Bio, Inc. reported Q1 2026 revenue of $17.0M (+71.5% YoY), beat analyst consensus of $4.7M by $12.3M. Diluted EPS came in at $-0.20 (-25.0% YoY), missed the $-0.17 consensus by $0.03.

Revenue
$17.0Mbeat by $12.3M
Consensus: $4.7M
Diluted EPS
$-0.20missed by $0.03
Consensus: $-0.17
SEC

SEC Filings

Earnings release8-K · 0001728117-26-000036
Quarterly report10-Q · 0001728117-26-000032

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Gossamer Bio, Inc.'s Q1 2026 earnings report.

Gossamer Bio, Inc. (GOSS) reported Q1 2026 earnings on May 18, 2026 before market open.

Gossamer Bio, Inc. reported revenue of $17.0M and diluted EPS of $-0.20 for Q1 2026.

Revenue beat the consensus estimate of $4.7M by $12.3M. EPS missed the consensus estimate of $-0.17 by $0.03.

Compared to the same quarter a year prior, revenue grew 71.5% from $9.9M a year earlier and diluted EPS declined 25.0% from $-0.16.

You can read the 8-K earnings release (0001728117-26-000036) and the 10-Q periodic report (0001728117-26-000032) directly on SEC EDGAR. The filing index links above go to sec.gov.